{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/APV40005","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00240552","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"","arm_groups":[],"assignment":"","brief_summary":"This open-label study will enable HIV-infected adults with limited treatment options to receive fosamprenavir until commercial supplies are available in Switzerland.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Fosamprenavir Expanded Access","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:44:23","criteria":"Inclusion Criteria: - HIV-1 infected subjects. - Subjects must belong to one of the following populations: 1) Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs. 2) Subjects who already receive amprenavir (Agenerase®) 3) Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"85","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"351d17a6-8b59-5385-8f34-c1c84ad07aa4","internal":{"content":null,"contentDigest":"765f4bd04ae69244266bb157ce88d156","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - HIV-1 infected subjects. - Subjects must belong to one of the following populations: 1) Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs. 2) Subjects who already receive amprenavir (Agenerase®) 3) Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.","interventions":[{"arm_group_label":"","intervention_description":"","intervention_name":"fosamprenavir","intervention_type":"Drug"},{"arm_group_label":"","intervention_description":"","intervention_name":"Telzir®","intervention_type":"Drug"}],"interventional_subtype":"","is_fda_regulated":null,"is_high_value":false,"is_ind_study":false,"keywords":["protease inhibitor","Treatment Experienced","amprenavir","fosamprenavir","GW433908","HIV","pro drug"],"last_follow_up_date":"08/01/2005 00:00:00","links":[],"locations":[{"City":"Basel","Latitude":"47.5595986","CountryDisplay":"Switzerland","Longitude":"7.5885761","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"4031","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lugano","Latitude":"46.009366","CountryDisplay":"Switzerland","Longitude":"8.9507851","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"6900","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bruderholz","Latitude":"47.5284281","CountryDisplay":"Switzerland","Longitude":"7.5811836","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"4101","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lausanne","Latitude":"46.5196535","CountryDisplay":"Switzerland","Longitude":"6.6322734","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"1011","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Luzern","Latitude":"47.0501682","CountryDisplay":"Switzerland","Longitude":"8.3093072","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"6000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bern","Latitude":"46.9475044","CountryDisplay":"Switzerland","Longitude":"7.423628","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"3010","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"St Gallen","Latitude":"47.4244818","CountryDisplay":"Switzerland","Longitude":"9.3767173","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"9007","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Zurich","Latitude":"47.359081","CountryDisplay":"Switzerland","Longitude":"8.5529168","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"8008","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"La Chaux-de-Fonds","Latitude":"47.1034892","CountryDisplay":"Switzerland","Longitude":"6.8327838","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"CH 2301","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Aarau","Latitude":"47.390434","CountryDisplay":"Switzerland","Longitude":"8.0457015","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"5001","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Zurich","Latitude":"47.3768866","CountryDisplay":"Switzerland","Longitude":"8.541694","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"8091","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Zurich","Latitude":"47.340415","CountryDisplay":"Switzerland","Longitude":"8.5294711","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"8038","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 23:00:25","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"An open-label phase III study to provide access to fosamprenavir and to assess the long term safety and tolerability of fosamprenavir containing regimens in HIV Infected patients with limited treatment options","org_study_id":"APV40005","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"4","primary_compl_date":null,"primary_outcomes":[],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GSK"]},"start_date":"07/01/2003 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":null}},"pageContext":{"studyId":"APV40005"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}